Scarica l'app Stockscreener
68.18
1.52%
-1.05
Dopo l'orario di chiusura:
68.20
0.02
+0.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$69.23
Aprire:
$68.92
Volume 24 ore:
4.43M
Relative Volume:
0.89
Capitalizzazione di mercato:
$26.74B
Reddito:
$4.30B
Utile/perdita netta:
$571.50M
Rapporto P/E:
47.73
EPS:
1.4285
Flusso di cassa netto:
$570.80M
1 W Prestazione:
-3.56%
1M Prestazione:
+2.59%
6M Prestazione:
-4.38%
1 anno Prestazione:
-5.62%
Intervallo 1D:
$67.80
$69.10
Intervallo di 1 settimana:
$66.42
$72.08
Portata 52W:
$57.52
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Confronta DXCM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
68.18 | 27.15B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
124.43 | 220.36B | 43.84B | 13.94B | 6.78B | 7.9979 |
|
BSX
Boston Scientific Corp
|
100.30 | 149.61B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
369.59 | 143.72B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
91.73 | 119.58B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
82.69 | 48.25B | 5.69B | 1.41B | 577.90M | 6.9828 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
DEXCOM ALERT: Bragar Eagel & Squire, P.C. Announces that a - GlobeNewswire
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Will breakout in DexCom Inc. lead to full recovery2025 Winners & Losers & Precise Trade Entry Recommendations - newser.com
What does recent volatility data suggest for DexCom Inc.2025 Support & Resistance & Fast Entry Momentum Trade Alerts - newser.com
Can technical indicators confirm DexCom Inc.’s reversal2025 Short Interest & Daily Profit Focused Screening - newser.com
DexCom Inc. stock daily chart insightsEarnings Risk Report & Weekly Watchlist for Consistent Profits - newser.com
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit - Morningstar
DexCom (DXCM) Expands Board with Appointment of Dr. Euan Ashley - GuruFocus
DCXM ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of DexCom, Inc. Investors - The AI Journal
Rosen Law Firm Urges DexCom, Inc. (NASDAQ: DXCM) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - The AI Journal
Portnoy Law Firm Announces Class Action on Behalf of DexCom, Inc. Investors - GlobeNewswire
DexCom Faces New Reports Of Deaths Linked To G7 Glucose Monitor - Benzinga
DexCom (DXCM) Shares Dip as Hunterbrook Issues Short Report - GuruFocus
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed DexCom, Inc. (DXCM) - GlobeNewswire Inc.
Dexcom Shares Slide After Short Seller Flags 3 Additional Deaths From G7 Devices - Stocktwits
DexCom falls as Hunterbrook releases new short report (DXCM:NASDAQ) - Seeking Alpha
AstraZeneca non-executive director Euan Ashley joins DexCom board By Investing.com - Investing.com Nigeria
DexCom Shares Fall After Hunterbrook Report on Incidents Related to G7 Glucose Monitor - MarketScreener
Dexcom (DXCM) Faces Scrutiny Following Reports of Glucose Monito - GuruFocus
DexCom (DXCM) Shares Fall 2% Following Short Report - GuruFocus
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Can Dexcom Deliver Strong Q3 Earnings on Stelo Gains and G7 Adoption? - Yahoo Finance
AstraZeneca non-executive director Euan Ashley joins DexCom board - Investing.com
DexCom: Powering The Future Of Glucose Monitoring And Digital Care - RTTNews
Is DexCom Inc. (DC4) stock a buy for dividend portfoliosTrade Analysis Summary & Verified Entry Point Detection - newser.com
What MACD trends signal for DexCom Inc. (DC4) stockJuly 2025 Breakouts & Reliable Trade Execution Plans - newser.com
What catalysts could drive DexCom Inc. stock higherTrade Exit Report & Consistent Profit Trading Strategies - newser.com
How DexCom Inc. stock performs in interest rate cyclesQuarterly Growth Report & Technical Entry and Exit Tips - Fundação Cultural do Pará
Is DexCom Inc. stock reversal real or fakeMarket Growth Report & Risk Managed Investment Entry Signals - newser.com
Can DexCom Inc. stock sustain free cash flow growthMarket Sentiment Review & Free Technical Pattern Based Buy Signals - newser.com
DexCom Inc. stock chart pattern explainedWeekly Profit Analysis & AI Based Trade Execution Alerts - newser.com
Will DexCom Inc. stock maintain momentum in 2025Quarterly Trade Summary & AI Forecasted Entry and Exit Points - newser.com
Dexcom appoints Stanford’s Euan Ashley to board of directors - Investing.com
Dexcom appoints Stanford’s Euan Ashley to board of directors By Investing.com - Investing.com Nigeria
Dexcom appoints Euan Ashley to board of directors - MarketScreener
Dexcom Appoints Euan Ashley To Board Of Directors - TradingView
Dexcom Appoints Euan Ashley to Board of Directors - The Joplin Globe
DexCom, Inc. Experiences Valuation Adjustment Amidst Competitive Market Landscape - Markets Mojo
Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights - The AI Journal
Is DexCom Inc. stock attractive for passive investorsDay Trade & Weekly Top Stock Performers List - newser.com
What MACD and RSI say about DexCom Inc.Portfolio Risk Summary & Free Technical Pattern Based Buy Signals - newser.com
Will a bounce in DexCom Inc. offer an exit2025 Volume Leaders & Long-Term Capital Growth Ideas - newser.com
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.10%
1.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):